Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Wyden biomaterials inquiry

This article was originally published in The Gray Sheet

Executive Summary

Staffers from Rep. Ron Wyden's (D-Ore.) office request a meeting with FDA officials to discuss biomaterials availability. Wyden had written HHS Secretary Donna Shalala about potential biomaterials shortages in the spring ("The Gray Sheet" May 9, p. 25). Shalala responded that HHS shares "your desire to avoid any needless disruption to the availability of" permanent implants. Acknowledging that "shortages of biomaterials may occur" with potentially "severe" consequences, Shalala outlined "actions taken" by the department that "demonstrate a commitment to ensuring" American leadership in the area of medical technology



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts